<SEC-DOCUMENT>0001564590-22-000853.txt : 20220110
<SEC-HEADER>0001564590-22-000853.hdr.sgml : 20220110
<ACCEPTANCE-DATETIME>20220110163104
ACCESSION NUMBER:		0001564590-22-000853
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20220110
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220110
DATE AS OF CHANGE:		20220110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EyePoint Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				262774444
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51122
		FILM NUMBER:		22521617

	BUSINESS ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-926-5000

	MAIL ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida Corp.
		DATE OF NAME CHANGE:	20080619

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida LTD
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>eypt-8k_20220110.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-01-10T21:02:30.8063525+00:00 -->
<!-- Version            : 5.0.1.725 -->
<!-- Package ID         : 71f793e6bdfa47c59d8acbe55a0d482d -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:eypt="http://eyepointpharma.com/20220110" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
eypt-8k_20220110.htm
</title>
</head>
<!-- NG Converter v5.0.2.67 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001314102_20220110_20220110">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0001314102_20220110_20220110">0001314102</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="eypt-20220110.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001314102_20220110_20220110">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-10</xbrli:startDate>
					<xbrli:endDate>2022-01-10</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Double 2.25pt;padding-bottom:1pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, DC 20549</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:37.73%;margin-right:37.59%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001314102_20220110_20220110">8-K</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:37.73%;margin-right:37.59%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) of the </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001314102_20220110_20220110" format="ixt:datemonthdayyearen">January 10, 2022</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:37.73%;margin-right:37.59%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0001314102_20220110_20220110">EyePoint Pharmaceuticals, Inc.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in Charter)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:37.73%;margin-right:37.59%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:34.02%;"></td>
<td style="width:1%;"></td>
<td style="width:31.99%;"></td>
<td style="width:1%;"></td>
<td style="width:31.99%;"></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001314102_20220110_20220110" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityFileNumber" contextRef="C_0001314102_20220110_20220110">000-51122</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001314102_20220110_20220110">26-2774444</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0001314102_20220110_20220110">480 Pleasant Street</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0001314102_20220110_20220110">Watertown</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0001314102_20220110_20220110">MA</ix:nonNumeric> <ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0001314102_20220110_20220110">02472</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices, and Zip Code) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0001314102_20220110_20220110">(617)</ix:nonNumeric> <ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0001314102_20220110_20220110">926-5000</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:37.73%;margin-right:37.59%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.66%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:WrittenCommunications" contextRef="C_0001314102_20220110_20220110" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.66%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:SolicitingMaterial" contextRef="C_0001314102_20220110_20220110" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.66%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:PreCommencementTenderOffer" contextRef="C_0001314102_20220110_20220110" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.66%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0001314102_20220110_20220110" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:34.2%;"></td>
<td style="width:1%;"></td>
<td style="width:31.9%;"></td>
<td style="width:1%;"></td>
<td style="width:31.9%;"></td>
</tr>
<tr>
<td valign="bottom" style=" border-bottom:solid 1pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">each class</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">on which registered</p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:Security12bTitle" contextRef="C_0001314102_20220110_20220110">Common Stock, par value $0.001</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001314102_20220110_20220110">EYPT</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:SecurityExchangeName" contextRef="C_0001314102_20220110_20220110" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2). </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000006" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001314102_20220110_20220110" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Double 2.25pt;padding-bottom:1pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 5.02. Departure of Directors or Certain Officers&#59; Election of Directors&#59; Appointment of Certain Officers&#59; Compensatory Arrangements of Certain Officers.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 10, 2022 (the &#8220;<span style="text-decoration:underline;">Start Date</span>&#8221;), EyePoint Pharmaceuticals, Inc. (the &#8220;<span style="text-decoration:underline;">Company</span>&#8221;) announced that the Board of Directors (the &#8220;<span style="text-decoration:underline;">Board</span>&#8221;) of the Company appointed Michael C. Pine, age 46, as the Company&#8217;s Chief Corporate Development and Strategy Officer. Mr.&#160;Pine was appointed Chief Corporate Development and Strategy Officer by the Board on January 7, 2022.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with Mr. Pine&#8217;s appointment, the Company entered into an employment agreement (the &#8220;<span style="text-decoration:underline;">Employment Agreement</span>&#8221;) with Mr. Pine, which provides that his employment will continue until either the Company or Mr. Pine provides notice of termination in accordance with the terms of the Employment Agreement. In addition, the Company entered into a confidential information, non-disclosure, non-solicitation, non-compete, and rights to intellectual property agreement with Mr. Pine, which prohibits him from competing with the Company, soliciting the Company&#8217;s employees and customers and disclosing confidential information during the term of his employment and for a specified time thereafter.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Employment Agreement, Mr. Pine is entitled to receive an annual base salary of $420,000 and a sign-on bonus totaling $108,000 (the &#8220;<span style="text-decoration:underline;">Sign-On Bonus</span>&#8221;). The Sign-On Bonus is payable in two equal tranches of $54,000, with the first tranche payable on the first regular payroll date following the Start Date, and the second tranche payable three months after the first tranche.&#160;&#160;The Sign-On Bonus is subject to partial or full forfeiture, as specified in the Employment Agreement, if Mr. Pine voluntarily terminates employment with the Company without good cause, or if the Company terminates Mr. Pine&#8217;s employment for cause, within the first fifteen months following the Start Date. In connection with his employment, the Company also granted Mr. Pine options to purchase 100,000 shares of the Company&#8217;s common stock at an exercise price of $12.62 per share,&#160;with 25% vesting on the first anniversary of the Start Date followed by ratable monthly vesting through the fourth anniversary of the Start Date.&#160;The Equity Awards were made outside the Company&#8217;s 2016 Long Term Equity Incentive Plan, as amended, as an inducement material to Mr. Pine&#8217;s entering into employment with the Company pursuant to Nasdaq Stock Market LLC (&#8220;<span style="text-decoration:underline;">Nasdaq</span>&#8221;) Listing Rule 5635(c)(4). In addition, Mr. Pine is eligible to receive an annual cash bonus, which is based on the achievement of individual and corporate performance objectives, calculated as a percentage of his annual base salary, and which will be determined by the Company&#8217;s Board, in its sole discretion. Mr. Pine&#8217;s target annual bonus is 45% of his annual base salary. In connection with his appointment, Mr. Pine has also entered into the Company&#8217;s standard indemnification agreement, the form of which is filed as Exhibit 10.19 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Employment Agreement, if Mr. Pine&#8217;s employment is terminated by the Company without &#8220;cause&#8221; or by Mr. Pine for &#8220;good cause&#8221; (as such terms are defined in the Employment Agreement), Mr. Pine will be entitled to (a)&#160;his base salary for the period of 12 months from the date of termination&#59; (b) 100% of his target bonus, payable in equal installments during the period of base salary continuation payable in clause (a)&#59; and (c)&#160;reimbursements equal to the portion of the monthly health premiums paid by the Company on Mr. Pine&#8217;s behalf and that of his eligible dependents immediately preceding the date that Mr. Pine&#8217;s employment terminates until the earlier of (i)&#160;the last day of the period of base salary continuation under clause (a)&#160;and (ii) that date that Mr. Pine and his eligible dependents become ineligible for COBRA coverage. Upon a &#8220;change of control&#8221; (as such term is defined in the Employment Agreement), any options to purchase shares of the Company&#8217;s common stock or shares of restricted stock of the Company held by Mr. Pine that are not fully vested at the time of the change of control will immediately accelerate and vest in full, provided that Mr. Pine is employed by the Company on the date of the change of control.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the payments set forth in the preceding paragraph, upon the termination of Mr. Pine&#8217;s employment for any reason, Mr. Pine will be entitled to receive any earned or accrued amounts and vested benefits that remain unpaid as of the date of his termination of employment. The payments and benefits set forth above are subject to Mr. Pine&#8217;s execution of a release of claims.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Pine brings over 20 years of experience in the pharmaceutical industry, serving in various business development and strategy roles. Most recently, Mr. Pine was a Senior Vice President of Business Development and Strategy at Medexus Pharmaceuticals, where he identified, evaluated and executed several transactions critical to the growth of the organization. Mr. Pine held roles of increasing responsibility at Lupin Pharmaceuticals, Aralez Pharmaceuticals, and Novartis Pharmaceuticals, where he spent over eight years building a diverse skill set in business development, commercial, operational and strategy roles. Earlier in his career, Mr. Pine was in business development roles at Kos Pharmaceuticals, Organon Biosciences, and Pfizer, as well as an Investment Banking Analyst at JP Morgan Chase. Mr. Pine holds a B.S. in Consumer Economics from Cornell University and an M.B.A from Columbia Business School. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no family relationships between Mr. Pine and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The description of the Employment Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the complete text of the Employment Agreement, a copy of which is filed as Exhibit 10.1 to this current report on Form 8-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:18pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="FIS_CHANGE_IN_DIRECTORS_OR_PRINCIPAL_OFF">&#160;<span style="font-weight:bold;font-size:10pt;color:#000000;">Item&#160;8.01. Other Events. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the Start Date, the Company issued a press release announcing the appointment of Mr. Pine.&#160;A copy of the press release, which is filed with this Current Report on Form 8-K as Exhibit 99.1, is hereby filed pursuant to this Item 8.01.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01. Financial Statements and Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:9.94%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="bottom" style="width:2%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:88.06%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:90.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="width:2%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eypt-ex101_8.htm"><span style="text-decoration:underline;">Employment Agreement, dated January 10, 2022, by and between EyePoint Pharmaceuticals, Inc. and Michael, C. Pine</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:9.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom" style="width:2%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eypt-ex991_9.htm"><span style="text-decoration:underline;">Press Release of EyePoint Pharmaceuticals, Inc., dated January 10, 2022</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:9.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" style="width:2%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the inline XBRL document)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:99.96%;">
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">EyePoint Pharmaceuticals, Inc.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: January 10, 2022</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ George O. Elston</p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">George O. Elston</p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>eypt-ex101_8.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eypt-ex101_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.67 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;margin-left:1.23%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.46%;">Exhibit 10.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gxexev5kvbsp000001.jpg" title="" alt="" style="width:137px;height:82px;"><font style="text-decoration:none;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:3.85%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EMPLOYMENT AGREEMENT</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.57%;text-indent:7.78%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:1.23%;text-indent:6.46%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Employment Agreement (hereinafter the &#8220;Agreement&#8221;) is made as of January 5, 2022, by and between <font style="font-weight:bold;">Michael Pine</font>, who currently resides at <font style="color:#333333;">xxx</font><font style="color:#333333;font-size:11.5pt;font-family:Noto Sans;"> </font>(&#8220;Employee&#8221;) and <font style="font-weight:bold;">EyePoint Pharmaceuticals, Inc. </font>(hereinafter together with its subsidiaries, and related or affiliated entities referred to as the &#8220;Company&#8221;), having its headquarters at 480 Pleasant Street, Suite A210, Watertown, Massachusetts 02472 (collectively the &#8220;Parties&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recitals</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Employee desires to be employed by and the Company desires to employ Employee as its Chief Corporate Development &amp; Strategy Officer; and </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:7.78%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">WHEREAS, the Company and Employee desire to set forth the terms and conditions under which the Company agrees to employ Employee and Employee agrees to be employed by the Company;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Company and the Employee hereby agree as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.57%;text-indent:7.78%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  </font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Position and</font><font style="text-decoration:underline;font-size:12pt;letter-spacing:-2.55pt;color:#000000;"> </font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Duties</font><font style="font-size:12pt;color:#000000;">.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="font-size:12pt;color:#000000;">Employee will</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">commence</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">employment on January 10, 2022</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">other</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">date as</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company</font><font style="font-size:12pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and Employee</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">may</font><font style="font-size:12pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">agree</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">(the</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">"</font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Start</font><font style="text-decoration:underline;font-size:12pt;letter-spacing:0.1pt;color:#000000;"> </font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Date</font><font style="font-size:12pt;color:#000000;">")</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">on</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">a</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> full-</font><font style="font-size:12pt;color:#000000;">time</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">basis, as the Chief Corporate Development &amp; Strategy Officer, reporting to the Chief Executive Officer (&#8220;CEO&#8221;) of the Company. This is an exempt position.&nbsp;&nbsp;During Employee&#8217;s employment, Employee may be asked from time to time to serve as a director or officer of one or more of the Company's subsidiaries, in each case, without further compensation. If Employee&#8217;s employment with the Company terminates for any reason, then concurrently with such termination, Employee will be deemed to have resigned from any director, officer, trustee, or other positions Employee may hold with the Company, the Company's subsidiaries, or any of their respective related committees, trusts, or other similar entities, in each case unless otherwise agreed in writing by</font><font style="font-size:12pt;letter-spacing:-2.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the Company and Employee.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="font-size:12pt;color:#000000;">Employee agrees to perform the duties of Employee&#8217;s position and such other duties as may reasonably be assigned to Employee consistent therewith from time to time. Employee also agrees that, while employed by the Company, Employee will devote Employee&#8217;s full business time and best efforts, business judgment, skill and knowledge exclusively to the advancement of the business interests of the Company and to the discharge of all assigned duties and responsibilities for them.&nbsp;&nbsp;This does not preclude the Employee from serving on Advisory and Corporate Boards, so long as doing so does not conflict or interfere with (i) the performance of Employee&#8217;s duties and responsibilities pursuant to this Agreement or (ii) the advancement of the Company&#8217;s business interests to the best of Employee&#8217;s ability.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="font-size:12pt;color:#000000;">Employee agrees that, while employed by the Company, Employee will comply with all Company policies, practices and procedures and all codes of ethics or business conduct applicable to Employee&#8217;s position, as in effect from time to time.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:16.87%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-size:11pt;font-weight:normal;margin-left:78pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Compensation and Benefits</font><font style="color:#000000;">. </font><font style="font-weight:normal;color:#000000;">During Employee&#8217;s employment, as compensation for all services performed by Employee for the Company and its subsidiaries and subject to Employee&#8217;s full performance</font><font style="letter-spacing:0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">of</font><font style="letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> Employee&#8217;s</font><font style="letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">obligations</font><font style="letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">hereunder,</font><font style="letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">the</font><font style="letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">Company</font><font style="letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">will</font><font style="letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">provide</font><font style="letter-spacing:0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">Employee</font><font style="letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">the</font><font style="letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">following</font><font style="letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">pay</font><font style="letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">and benefits:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Base</font><font style="text-decoration:underline;font-size:12pt;letter-spacing:1.35pt;color:#000000;"> </font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Salary</font><font style="font-size:12pt;color:#000000;">.&nbsp;&nbsp;The Company will pay Employee a base salary at the rate of Four Hundred Twenty Thousand Dollars ($420,000) per year, payable in accordance with the regular payroll practices of the Company (as may be adjusted, from time to time, the "Base Salary").</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Sign-On Bonus</font><font style="font-size:12pt;color:#000000;">.&nbsp;&nbsp;Employee shall be entitled to receive a total of $108,000 (the &#8220;</font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Sign-On Bonus</font><font style="font-size:12pt;color:#000000;">&#8221;), subject to applicable payroll taxes and withholdings, payable as follows:&nbsp;&nbsp;(i) $54,000 to be paid upon the first regular payroll date after the Start Date; and, provided that Employee has not been terminated for Cause and has not voluntarily terminated employment with the Company without Good Cause; (ii) $54,000 (the &#8220;</font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Second Tranche</font><font style="font-size:12pt;color:#000000;">&#8221;) payable on the first regular payroll date after the date that is three (3) months after the Start Date.&nbsp;&nbsp;Notwithstanding the foregoing, in the event that, (x) on or before the twelve-month anniversary of the Start Date, Employee voluntarily terminates employment with the Company without Good Cause, or Employee&#8217;s employment is terminated for Cause, the entire Sign-On Bonus paid to Employee prior to such employment termination event shall be subject to forfeiture, and the net amount of the Sign-On Bonus (after withheld taxes) shall be repaid by Employee to the Company within three (3) business days following such termination event or (y) between and including the twelve-month anniversary of the Start Date and the fifteen-month anniversary of the Start Date, Employee voluntarily terminates employment with the Company without Good Cause, or Employee&#8217;s employment is terminated for Cause, the Second Tranche shall be subject to forfeiture, and the net amount of the Second Tranche (after withheld taxes) shall be repaid by Employee to the Company within three (3) business days following such termination event.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:4pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Bonus Compensation</font><font style="font-size:12pt;color:#000000;">. For each fiscal year completed during Employee&#8217;s employment under this Agreement, Employee will be eligible for an annual cash bonus. Employee&#8217;s target bonus will be 45% of the Base Salary (the "</font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Target Bonus</font><font style="font-size:12pt;color:#000000;">"), with the actual amount of any such bonus being determined by the Board of Directors of the Company (the "</font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Board</font><font style="font-size:12pt;color:#000000;">") in its sole discretion, based on Employee&#8217;s performance and that of the Company against </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;margin-left:1.23%;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="font-size:12pt;color:#000000;">goals established by the Board</font><font style="font-size:12pt;color:#000000;"> and consistent with any applicable plan or program documents</font><font style="font-size:12pt;color:#000000;"> and generally applicable Company policies</font><font style="font-size:12pt;color:#000000;">. </font><font style="font-size:12pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Exce</font><font style="font-size:12pt;color:#000000;">pt as otherwise</font><font style="font-size:12pt;color:#000000;"> expressly provided in Section 4</font><font style="font-size:12pt;color:#000000;"> hereof, </font><font style="font-size:12pt;color:#000000;">Employee</font><font style="font-size:12pt;color:#000000;"> must be employed through</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">date</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">a</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">bonus</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">is</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">paid</font><font style="font-size:12pt;letter-spacing:-0.8pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">order</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;color:#000000;"> earn</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">bonus.</font><font style="font-size:12pt;color:#000000;">&nbsp;&nbsp;If </font><font style="font-size:12pt;color:#000000;">Employee&#8217;s</font><font style="font-size:12pt;color:#000000;"> employment terminates, for any reason, prior to payout of the bonus, the bonus is not earned.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:4pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Participation in Employee Benefit Plans</font><font style="font-size:12pt;color:#000000;">. Employee will be entitled to participate in the Company&#8217;s employee benefit plans in effect for employees of the Company generally, except to the extent such plans are duplicative of benefits otherwise provided Employee under this Agreement (e.g., a severance pay plan). Employee&#8217;s participation will be subject to the terms of the applicable plan documents and generally applicable Company policies, as the same may be in effect from time to time, and any other restrictions or limitations imposed by</font><font style="font-size:12pt;letter-spacing:-1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">law.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Vacations</font><font style="font-size:12pt;color:#000000;">. Employee will be entitled to four (4) weeks of vacation per year, in addition to holidays observed by the Company.&nbsp;&nbsp;Vacation will accrue monthly on a pro-rated basis. Vacation may be taken at such times and intervals as Employee shall determine, subject to the business needs of the Company. Vacation shall</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">otherwise</font><font style="font-size:12pt;letter-spacing:0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">be</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">subject</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">policies</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company,</font><font style="font-size:12pt;letter-spacing:0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">as</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">effect</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">from</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">time</font><font style="font-size:12pt;letter-spacing:-0.85pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">time.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Business Expenses</font><font style="font-size:12pt;color:#000000;">. The Company will pay or reimburse Employee for all reasonable business expenses incurred or paid by Employee in the performance of Employee&#8217;s duties and responsibilities for the Company, subject to any maximum annual limit and other restrictions on such expenses set by the Company and to such reasonable substantiation and documentation as may be specified from time to time. Employee&#8217;s right to payment or reimbursement for business expenses hereunder shall be subject to the following additional rules: (i) the amount of expenses eligible for payment or reimbursement during any calendar year shall not affect the expenses eligible</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">for</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">payment</font><font style="font-size:12pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">reimbursement</font><font style="font-size:12pt;letter-spacing:0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">other</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">calendar</font><font style="font-size:12pt;letter-spacing:0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">year,</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">(ii)</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">payment or</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">reimbursement shall be made not later than December 31 of the calendar year following the calendar year in which the expense or payment was incurred, and (iii) the right to payment or reimbursement is not</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">subject</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">liquidation</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">exchange</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">for</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">other</font><font style="font-size:12pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">benefit.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-size:11pt;font-weight:normal;margin-left:78pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination</font><font style="text-decoration:underline;letter-spacing:0.5pt;color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">of Employment</font><font style="color:#000000;">. </font><font style="font-weight:normal;color:#000000;">Employee&#8217;s employment under this</font><font style="letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">Agreement</font><font style="letter-spacing:0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">shall</font><font style="letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">continue</font><font style="letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">until</font><font style="letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">terminated</font><font style="letter-spacing:-0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">pursuant</font><font style="letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">to</font><font style="letter-spacing:-0.95pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">this</font><font style="letter-spacing:-0.95pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">Section</font><font style="letter-spacing:-1.05pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">3.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><a name="_Hlk514751984"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">By the Company for Cause</font><font style="font-size:12pt;color:#000000;">. The Company may terminate Employee&#8217;s employment for Cause upon notice to Employee<a name="_Hlk514751984"></a> setting forth in reasonable detail the nature of the Cause. The following, as determined by the Board in its reasonable, good faith judgment, shall constitute "</font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Cause</font><font style="font-size:12pt;color:#000000;">" for termination: (i) material or willful failure to perform duties reasonably expected and/or requested of Employee (other than by reason of disability) if not cured within 30 days of written notice of such failure; (ii) material breach of this Agreement or any other agreement between Employee and the Company, including but not limited to any Confidential Information, Non-Disclosure, Non-Solicitation, Non-Compete, and Rights to Intellectual Property Agreement if not cured within 30 days of written notice of such breach; (iii) commission of, or plea of nolo contendere to, a felony or other crime involving moral turpitude; (iv) commission of fraudulent or illegal act in commission of </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;margin-left:1.23%;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="font-size:12pt;color:#000000;">Employee&#8217;s</font><font style="font-size:12pt;color:#000000;"> duties or otherwise with respect to the Company; (v) failure to adhere to moral and ethical business principles consistent with the Company&#8217;s Code of Business Conduct and/or policies in effect from time to time; </font><font style="font-size:12pt;color:#000000;">(vi) </font><font style="font-size:12pt;color:#000000;">engaging in an act or series of acts constituting misconduct resulting in a misstatement of the Company's&nbsp;&nbsp;financial statements due to material non-compliance with any financial reporting requirement within the meaning of Section 304 of the Sarbanes-Oxley Act of 2002; or (vii)</font><font style="font-size:12pt;color:#000000;"> other conduct that is or could reasonably be expected to be harmful to the interests or reputation</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-1.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company</font><font style="font-size:12pt;color:#000000;">.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:1.29%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">By the Company Without Cause</font><font style="font-size:12pt;color:#000000;">. The Company may terminate Employee&#8217;s employment</font><font style="font-size:12pt;letter-spacing:0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">at</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">time</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">other</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">than</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">for</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Cause</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">upon</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> thirty (30) days&#8217; notice to employee.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.26%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">By Employee for Good Cause</font><font style="font-size:12pt;color:#000000;">. Employee may terminate Employee&#8217;s employment for Good Cause by (A) providing notice to the Company specifying in reasonable detail the condition giving</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">rise</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Good</font><font style="font-size:12pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Cause no</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">later</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">than</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">thirtieth</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">(30th)</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">day</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">following</font><font style="font-size:12pt;letter-spacing:0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Employee&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">first</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">becoming aware of such event or condition; (B) providing the Company a period of (30) days to remedy the</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">event</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">condition;</font><font style="font-size:12pt;letter-spacing:0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">and</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">(C)</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> written notice </font><font style="font-size:12pt;color:#000000;">terminating</font><font style="font-size:12pt;letter-spacing:0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Employee&#8217;s employment</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">for</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Good</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Cause</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">within</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">fifteen</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">(15) days following the expiration of the period to remedy if the Company fails to remedy the condition. The following, if occurring without Employee&#8217;s consent, shall constitute "</font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Good Cause</font><font style="font-size:12pt;color:#000000;">" for termination by Employee: (i) a material diminution in the nature or scope of Employee&#8217;s position, duties, or authority (other than temporarily while Employee is physically or mentally incapacitated to such a degree that Employee would be eligible for disability benefits under the Company's disability income plan or as required by applicable law); (ii) a material reduction in the Base Salary or the Target Bonus percentage;</font><font style="font-size:12pt;letter-spacing:0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">(iii)</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">a</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">material</font><font style="font-size:12pt;letter-spacing:0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">breach</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">by</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company</font><font style="font-size:12pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.8pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">this</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Agreement; or (iv)</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">a</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">requirement by the Company that Employee relocate to a location more than forty (40) miles from Employee&#8217;s then-current remote office location.</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;"></font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">By Employee Without Good Cause</font><font style="font-size:12pt;color:#000000;">. Employee may terminate Employee&#8217;s employment at any time without Good Cause upon thirty (30) days' notice to the Company. The Board may elect</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">waive</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">notice</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">period</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">any</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">portion</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">thereof;</font><font style="font-size:12pt;letter-spacing:0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">but</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">that</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">event,</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Company shall</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">pay Employee the</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Base</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Salary</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">for</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">that</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">portion</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">notice</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">period</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">so</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">waived.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Death and Disability</font><font style="font-size:12pt;color:#000000;">. Employee&#8217;s employment hereunder shall automatically terminate in the event of Employee&#8217;s death during employment. In the event Employee becomes disabled during employment and, as a result, is unable to continue to perform substantially all of Employee&#8217;s duties and responsibilities under this Agreement, either with or without reasonable accommodation, the Company will continue to pay Employee the Base Salary and to provide Employee benefits in accordance with Section 2(d) above, to the extent permitted by plan terms, for up to twelve (12) weeks of disability during any period of three hundred sixty-five (365) consecutive calendar days. </font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:1.26%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-size:11pt;font-weight:normal;margin-left:78pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Other</font><font style="text-decoration:underline;letter-spacing:-1.85pt;color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Matters</font><font style="text-decoration:underline;letter-spacing:-0.85pt;color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Related</font><font style="text-decoration:underline;letter-spacing:-1.05pt;color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">to</font><font style="text-decoration:underline;letter-spacing:-1.45pt;color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Termination</font><font style="color:#000000;">.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-right:0.21%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:0.21%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Final Compensation</font><font style="font-size:12pt;color:#000000;">.</font><font style="font-size:12pt;letter-spacing:-1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">In the event of termination of Employee&#8217;s employment with the Company, howsoever occurring, the Company shall pay Employee (i) the Base Salary for the </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;margin-left:1.23%;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:0.21%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="font-size:12pt;color:#000000;">final payroll period of </font><font style="font-size:12pt;color:#000000;">Employee&#8217;s</font><font style="font-size:12pt;color:#000000;"> employment,</font><font style="font-size:12pt;color:#000000;"> pro-rated</font><font style="font-size:12pt;color:#000000;"> through the date that </font><font style="font-size:12pt;color:#000000;">Employee&#8217;s</font><font style="font-size:12pt;color:#000000;"> employment terminates; (ii) compensation at the rate of the Base Salary for any </font><font style="font-size:12pt;color:#000000;">accrued, unused </font><font style="font-size:12pt;color:#000000;">vacation time</font><font style="font-size:12pt;color:#000000;">; and (iii) reimbursement, in accordance with Section 2(</font><font style="font-size:12pt;color:#000000;">f</font><font style="font-size:12pt;color:#000000;">) hereof, for business expenses incurred by </font><font style="font-size:12pt;color:#000000;">Employee </font><font style="font-size:12pt;color:#000000;">but not yet paid to </font><font style="font-size:12pt;color:#000000;">Employee</font><font style="font-size:12pt;color:#000000;"> as of the date </font><font style="font-size:12pt;color:#000000;">Employee&#8217;s</font><font style="font-size:12pt;color:#000000;"> employment terminates; provided </font><font style="font-size:12pt;color:#000000;">Employee</font><font style="font-size:12pt;color:#000000;"> submit</font><font style="font-size:12pt;color:#000000;">s</font><font style="font-size:12pt;color:#000000;"> all expenses and supporting documentation required within sixty (60) days of the date </font><font style="font-size:12pt;color:#000000;">Employee&#8217;s</font><font style="font-size:12pt;color:#000000;"> employment terminates, and provided further that such expenses are reimbursable under Company policies as then in effect (all of the foregoing, "</font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Final Compensation</font><font style="font-size:12pt;color:#000000;">"). Except as otherwise provided in Section 5(a)(iii), Final Compensation will be paid to </font><font style="font-size:12pt;color:#000000;">Employee </font><font style="font-size:12pt;color:#000000;">within thirty (30) days following the date of termination (or such shorter period required by law).</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-right:0.21%;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:0.21%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Severance Payments</font><font style="font-size:12pt;color:#000000;">. In the event of any termination of Employee&#8217;s employment pursuant to Section 3(b) or Section </font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;">3(c) </font><font style="font-size:12pt;color:#000000;">above, the Company will pay Employee, in addition to Final Compensation, (i) the Base Salary for the period of twelve (12) months from the date of termination, provided, however, that if such termination occurs within twelve (12) months following the Start Date (a &#8220;</font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Year One Termination</font><font style="font-size:12pt;color:#000000;">&#8221;), the Company will instead pay Employee, in addition to Final Compensation, the Base Salary for a period of six (6) months from the date of termination, unless such Year One Termination occurs following a Change of Control, in which case the Company will instead pay employee the Base Salary for a period of twelve (12) months from the date of such post-Change of Control termination; (ii) one times the Target Bonus, or 0.5 times the Target Bonus in the event of a Year One Termination unless such Year One Termination occurs following a Change of Control, in which case the Company will instead pay employee one times the Target Bonus; in either case (i) or (ii), payable in equal installments during the period of Base Salary continuation under clause (i).&nbsp;&nbsp;Provided Employee timely elects continuation coverage for Employee and Employee&#8217;s eligible dependents under the federal law known as "COBRA" or similar</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">state law, the Company will pay the monthly amount that equals the portion of the monthly health premiums paid by the Company on Employee&#8217;s behalf and that of Employee&#8217;s eligible dependents immediately preceding the date that Employee&#8217;s employment terminates until the earlier of (A) the last day of the period of Base Salary continuation under clause (i) and (B) the date that Employee and Employee&#8217;s eligible dependents become ineligible for COBRA coverage to the extent permissible by law and plan terms. The severance payments described in clauses (i) through (ii) above are referred to as the "</font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Severance</font><font style="font-size:12pt;color:#000000;"> </font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Payments</font><font style="font-size:12pt;color:#000000;">".</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;"> In the event a Change of Control occurs following the Start Date, and any options to purchase Stock or shares of restricted Stock held by Employee are assumed or substituted in such Change of Control, all such assumed or substituted options and restricted shares that remain outstanding and are not fully vested at the time of any subsequent termination of Employee&#8217;s employment pursuant to Section 3(b) or Section 3(c) shall immediately accelerate and vest in full upon such termination (the &#8220;Equity Acceleration&#8221;).</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;margin-right:0.21%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:0.21%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Conditions to and Timing of Severance Payments</font><font style="font-size:12pt;color:#000000;">. Any obligation of the Company to provide Employee the Severance Payments and the Equity Acceleration is conditioned, however, on Employee&#8217;s cooperation in the transition of Employee&#8217;s duties and Employee&#8217;s execution and return to the Company of a Severance Agreement and General Release acceptable to the Company which shall include a release of all claims against the Company, all affiliated and related entities, and/or persons deemed necessary by the Company.&nbsp;&nbsp;The Release may also include Confidentiality, Non-Disparagement, No-Reapply, Tax Indemnification, and/or other appropriate </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;margin-left:1.23%;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:0.21%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="font-size:12pt;color:#000000;">terms.&nbsp;&nbsp;Except as otherwise provided by this Agreement, a</font><font style="font-size:12pt;color:#000000;">ny Severance Payments</font><font style="font-size:12pt;color:#000000;"> to which </font><font style="font-size:12pt;color:#000000;">Employee is</font><font style="font-size:12pt;color:#000000;"> entitled will be provided in the form of salary continuation, payable in accordance with the normal payroll practices of the Company. </font><font style="font-size:12pt;color:#000000;">Unless otherwise provided by this Agreement, t</font><font style="font-size:12pt;color:#000000;">he first payment will be made on the Company's next regular payday following the </font><font style="font-size:12pt;color:#000000;">effective date of the </font><font style="font-size:12pt;color:#000000;">Severance </font><font style="font-size:12pt;color:#000000;">Agreement</font><font style="font-size:12pt;color:#000000;"> and General Release</font><font style="font-size:12pt;color:#000000;">; but that first payment shall include all amounts</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">accrued</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">retroactive</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">day</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">following</font><font style="font-size:12pt;letter-spacing:-0.8pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">date</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Employe</font><font style="font-size:12pt;color:#000000;">e</font><font style="font-size:12pt;color:#000000;">&#8217;s </font><font style="font-size:12pt;color:#000000;">employment</font><font style="font-size:12pt;letter-spacing:0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">terminated.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;margin-right:0.21%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:0.21%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Benefits Termination</font><font style="font-size:12pt;color:#000000;">. Except as provided in Section 4(b) above or under COBRA, Employee&#8217;s participation in all employee benefit plans shall terminate in accordance with the terms of the applicable benefit plans based on the date of termination of Employee&#8217;s employment, without regard to any continuation of the Base Salary or other payment to Employee following termination and Employee shall not be eligible to earn vacation or other paid time off following the termination</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of Employee&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">employment.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:0.21%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Assistance in Litigation</font><font style="font-size:12pt;color:#000000;">.&nbsp;&nbsp;Employee agrees to reasonably cooperate with the Company in the defense or prosecution of any claims or actions that relate to events or occurrences that transpired while Employee is or was employed by the Company. Employee&#8217;s cooperation includes, but is not limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company as requested at mutually convenient times. Employee&#8217;s cooperation also includes fully cooperating with the Company in connection with any investigation or review by any federal, state, or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while Employee is or was employed by the Company.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.21%;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:0.21%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Survival</font><font style="font-size:12pt;color:#000000;">. Provisions of this Agreement shall survive any termination of employment if so provided in this Agreement or if necessary or desirable to accomplish the purposes of other surviving provisions, including without limitation Employee&#8217;s obligations under Section 4. The obligation of the Company to make payments to Employee under Section 4, are expressly conditioned upon continued full performance of Employee&#8217;s obligations under Section 4 hereof. Upon termination by either Employer or the Company, all rights, duties and obligations of Employee and the Company to each other shall cease, except as otherwise</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">expressly</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">provided</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">in</font><font style="font-size:12pt;letter-spacing:-0.8pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">this</font><font style="font-size:12pt;letter-spacing:-0.9pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25%;margin-right:0.21%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-size:11pt;font-weight:normal;margin-left:78pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Timing</font><font style="text-decoration:underline;letter-spacing:-1.05pt;color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">of Payments</font><font style="text-decoration:underline;letter-spacing:-1.05pt;color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">and</font><font style="text-decoration:underline;letter-spacing:-1pt;color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Section</font><font style="text-decoration:underline;letter-spacing:-0.6pt;color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">409A</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17.12%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="font-size:12pt;color:#000000;">Notwithstanding anything to the contrary in this Agreement, if at the time Employee&#8217;s employment terminates, Employee is a "specified employee," as defined below, any and all amounts payable under this Agreement on account of such separation from service that would (but for this provision) be payable within six (6) months following the date of termination, shall instead</font><font style="font-size:12pt;letter-spacing:0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">be</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">paid</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">on</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">next</font><font style="font-size:12pt;letter-spacing:0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">business</font><font style="font-size:12pt;letter-spacing:0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">day</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">following</font><font style="font-size:12pt;letter-spacing:0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">expiration</font><font style="font-size:12pt;letter-spacing:0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">six</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">(6)</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">month</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">period</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or, if</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">earlier,</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">upon</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Employee&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">death; except</font><font style="font-size:12pt;letter-spacing:0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">(A)</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">extent</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">amounts</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">that</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">do</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">not</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">constitute</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">a</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">deferral</font><font style="font-size:12pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of compensation within the meaning of Treasury regulation Section l.409A-1(b) (including without limitation&nbsp;&nbsp;by reason&nbsp;&nbsp;of&nbsp;&nbsp;a short-term&nbsp;&nbsp;deferral&nbsp;&nbsp;or the safe&nbsp;&nbsp;harbor&nbsp;&nbsp;set&nbsp;&nbsp;forth&nbsp;&nbsp;in Section&nbsp;&nbsp;l.409A&#173; l (b)(9)(iii), as determined by the Company in its reasonable good faith discretion); (B) benefits which qualify as excepted welfare benefits pursuant to Treasury regulation Section l.409A&#173; l(a)(5); or (C) other amounts or benefits that are not subject to the requirements </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;margin-left:1.23%;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="font-size:12pt;color:#000000;">of, or satisfy an exception from treatment as deferred compensation under, Section 409A of the Internal Revenue Code of 1986, as amended ("</font><font style="text-decoration:underline;font-size:12pt;color:#000000;">Section</font><font style="text-decoration:underline;font-size:12pt;letter-spacing:-1.8pt;color:#000000;"> </font><font style="text-decoration:underline;font-size:12pt;color:#000000;">409A</font><font style="font-size:12pt;color:#000000;">"). For purposes of this Agreement, all references to "termination of employment" and correlative phrases shall be construed to require a "separation from service" (as defined in Section l.409A-l(h) of the Treasury regulations after giving effect to the presumptions contained therein), and the term "specified employee" means an individual determined by the Company to be a specified employee under Treasury regulation Section l.409A-l(</font><font style="font-size:12pt;color:#000000;">i</font><font style="font-size:12pt;color:#000000;">).</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:4pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="font-size:12pt;color:#000000;">Each payment made under this Agreement shall be treated as a separate payment and</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">right</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">a</font><font style="font-size:12pt;letter-spacing:-0.8pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">series</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">installment</font><font style="font-size:12pt;letter-spacing:0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">payments</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">under</font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">this</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Agreement</font><font style="font-size:12pt;letter-spacing:0.15pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">is</font><font style="font-size:12pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">be</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">treated</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">as a</font><font style="font-size:12pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">right</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">a</font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">series</font><font style="font-size:12pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">separate payments.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="font-size:12pt;color:#000000;">In no event shall the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section</font><font style="font-size:12pt;letter-spacing:-1.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">409A.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-size:11pt;font-weight:normal;margin-left:78pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Definitions</font><font style="color:#000000;">. </font><font style="font-weight:normal;color:#000000;">For purposes of this Agreement, the following definitions apply: "</font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Change of Control</font><font style="font-weight:normal;color:#000000;">"</font><font style="letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">means</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:1pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:11pt;margin-left:65pt;color:#000000;"></font><font style="font-size:12pt;color:#000000;">The acquisition by any Person (defined for purposes of this definition as any individual, entity or group (within the meaning of Section 13(d)(3) or Section 14(d)(2) of the Securities Exchange Act of 1934, as amended ("Exchange Act")) of&nbsp;&nbsp;beneficial&nbsp;&nbsp;ownership (within the meaning of </font><font style="font-style:italic;font-size:12pt;color:#000000;">Rule </font><font style="font-size:12pt;color:#000000;">13d-3 promulgated under the Exchange Act) of 35% or more of the common stock of the Company; provided, however, that for purposes of this subsection (A), an acquisition shall not constitute a Change of Control if it is: (i) either by or directly from the Company, or by an entity controlled by the Company, (ii) by any employee benefit plan, including any related trust, sponsored or maintained by the Company or an entity controlled by the Company ("Benefit Plan"), or (iii) by an entity pursuant to a transaction that complies with clauses (i), (ii) and (iii) of</font><font style="font-size:12pt;letter-spacing:-2.2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">subsection (b) below; or Individuals who, as of the effective date of this Agreement, constitute the Board (together with the individuals&nbsp;&nbsp;identified&nbsp;&nbsp;in the proviso to&nbsp;&nbsp;this subsection&nbsp;&nbsp;(B), the</font><font style="font-size:12pt;letter-spacing:1.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">"Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the effective date of this agreement whose election, or nomination for election by the Company's stockholders, was approved by at least a majority of the directors then comprising the Incumbent Board shall be treated as a member of the Incumbent Board unless he or she assumed office as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or</font></p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;color:#000000;"></font><font style="font-size:12pt;color:#000000;">Consummation of a reorganization, merger or consolidation involving the Company, or a sale or other disposition of all or substantially all of the assets of the Company </font><font style="font-size:12pt;letter-spacing:-0.2pt;color:#000000;">(a </font><font style="font-size:12pt;color:#000000;">"Transaction"), in each case unless, following such Transaction, (i) all or substantially all of the Persons who were the beneficial owners of the common stock of the Company outstanding immediately prior to such Transaction beneficially own, directly or indirectly, more than 50% of the combined voting power of the then outstanding voting securities of the entity resulting from such Transaction (including, without limitation, an entity that as a result of such Transaction owns the Company or all or substantially all of the Company's assets either directly or through one or </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;margin-left:1.23%;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="font-size:12pt;color:#000000;">more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Transaction, of the outstanding common stock of the Company, (ii) no Person </font><font style="font-size:12pt;letter-spacing:-0.15pt;color:#000000;">(excluding </font><font style="font-size:12pt;color:#000000;">any entity or wholly-owned subsidiary of any entity resulting from such Transaction or any Benefit Plan of the Company or such entity or wholly-owned subsidiary of such entity resulting from such Transaction) beneficially owns, directly or indirectly, 35% or more of the combined voting power of the then outstanding voting securities of such entity except to the extent that such ownership existed prior to the transaction and (iii) at least a majority of the members of the board of directors or similar board of the entity resulting from such Transaction were members of the Incumbent Board at the time of the execution of the initial agreement, or of the</font><font style="font-size:12pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">action</font><font style="font-size:12pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">of</font><font style="font-size:12pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">the</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Board,</font><font style="font-size:12pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">providing</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">for</font><font style="font-size:12pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">such</font><font style="font-size:12pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Transaction;</font><font style="font-size:12pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">or</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11.5pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-size:11pt;margin-left:72pt;color:#000000;"></font><font style="font-size:12pt;color:#000000;">Approval by the stockholders of the Company of a liquidation or dissolution of the Company.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">"</font><font style="text-decoration:underline;">Person</font><font style="text-decoration:none;">" means an individual, a corporation, a limited liability company, an association, a</font><font style="text-decoration:none;letter-spacing:-1pt;"> </font><font style="text-decoration:none;">partnership,</font><font style="text-decoration:none;letter-spacing:0.5pt;"> </font><font style="text-decoration:none;">an</font><font style="text-decoration:none;letter-spacing:-0.65pt;"> </font><font style="text-decoration:none;">estate,</font><font style="text-decoration:none;letter-spacing:-0.4pt;"> </font><font style="text-decoration:none;">a</font><font style="text-decoration:none;letter-spacing:-1.1pt;"> </font><font style="text-decoration:none;">trust</font><font style="text-decoration:none;letter-spacing:-0.25pt;"> </font><font style="text-decoration:none;">or</font><font style="text-decoration:none;letter-spacing:-0.6pt;"> </font><font style="text-decoration:none;">any</font><font style="text-decoration:none;letter-spacing:-0.55pt;"> </font><font style="text-decoration:none;">other entity</font><font style="text-decoration:none;letter-spacing:-0.75pt;"> </font><font style="text-decoration:none;">or</font><font style="text-decoration:none;letter-spacing:-0.45pt;"> </font><font style="text-decoration:none;">organization,</font><font style="text-decoration:none;letter-spacing:0.05pt;"> </font><font style="text-decoration:none;">other</font><font style="text-decoration:none;letter-spacing:-0.4pt;"> </font><font style="text-decoration:none;">than</font><font style="text-decoration:none;letter-spacing:-0.5pt;"> </font><font style="text-decoration:none;">the</font><font style="text-decoration:none;letter-spacing:-0.5pt;"> </font><font style="text-decoration:none;">Company</font><font style="text-decoration:none;letter-spacing:0.25pt;"> </font><font style="text-decoration:none;">or</font><font style="text-decoration:none;letter-spacing:-0.45pt;"> </font><font style="text-decoration:none;">any of its</font><font style="text-decoration:none;letter-spacing:-1.75pt;"> </font><font style="text-decoration:none;">subsidiaries.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-size:11pt;font-weight:normal;margin-left:78pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Conflicting Agreements</font><font style="color:#000000;">. </font><font style="font-weight:normal;color:#000000;">Employee hereby represents and warrants that the signing of this Agreement and the performance of Employee&#8217;s obligations under it will not breach or be in conflict with</font><font style="letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">any</font><font style="letter-spacing:-0.25pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">other</font><font style="letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">agreement</font><font style="letter-spacing:0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">to</font><font style="letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">which</font><font style="letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">Employee is</font><font style="letter-spacing:-0.7pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">a</font><font style="letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">party or</font><font style="letter-spacing:-0.6pt;font-weight:normal;color:#000000;"> is</font><font style="letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">bound,</font><font style="letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">and</font><font style="letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">that</font><font style="letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">Employee is not</font><font style="letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">subject to</font><font style="letter-spacing:-0.25pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">any</font><font style="letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">covenants</font><font style="letter-spacing:0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">against</font><font style="letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">competition</font><font style="letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">or</font><font style="letter-spacing:-0.9pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">similar</font><font style="letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">covenants</font><font style="letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">or</font><font style="letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">any</font><font style="letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">court</font><font style="letter-spacing:-0.55pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">order</font><font style="letter-spacing:-0.25pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">that</font><font style="letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">could</font><font style="letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">affect</font><font style="letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">the performance of Employee&#8217;s obligations under this Agreement.&nbsp;&nbsp;Employee agrees that Employee will not disclose to or use on behalf of the Company any confidential or proprietary information of a third party without that party's</font><font style="letter-spacing:-0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">consent.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:16.61%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-size:11pt;font-weight:normal;margin-left:78pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Withholding</font><font style="color:#000000;">. </font><font style="font-weight:normal;color:#000000;">All payments made by the Company under this Agreement shall be reduced by any tax or other amounts required to be withheld by the Company under applicable</font><font style="letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">law.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:16.61%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-size:11pt;font-weight:normal;margin-left:78pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Assignment</font><font style="color:#000000;">. </font><font style="font-weight:normal;color:#000000;">Neither Employee nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">provided</font><font style="font-weight:normal;color:#000000;">, </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">however</font><font style="font-weight:normal;color:#000000;">, the Company may assign its rights and obligations under</font><font style="letter-spacing:-0.1pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">this</font><font style="letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">Agreement</font><font style="letter-spacing:0.05pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">without</font><font style="letter-spacing:0.15pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">Employee&#8217;s consent</font><font style="letter-spacing:-0.3pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">to</font><font style="letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">one</font><font style="letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">of</font><font style="letter-spacing:-0.85pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">its</font><font style="letter-spacing:-0.6pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">subsidiaries or</font><font style="letter-spacing:-0.7pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">to</font><font style="letter-spacing:-0.4pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">any</font><font style="letter-spacing:-0.5pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">Person with</font><font style="letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">whom the Company shall hereafter effect a reorganization, consolidate or merge, or to whom the Company shall hereafter transfer all or substantially all of its properties or assets. This Agreement shall inure to the benefit of and be binding upon Employee and the Company, and each of its respective</font><font style="letter-spacing:-0.65pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">successors,</font><font style="letter-spacing:-0.2pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">executors,</font><font style="letter-spacing:-0.35pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">administrators,</font><font style="letter-spacing:-0.75pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">heirs</font><font style="letter-spacing:-0.85pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">and</font><font style="letter-spacing:-0.75pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">permitted</font><font style="letter-spacing:-0.45pt;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">assigns.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:16.61%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-size:11pt;font-weight:normal;margin-left:78pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Severability</font><font style="color:#000000;">. </font><font style="font-weight:normal;color:#000000;">If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;margin-left:1.23%;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-size:11pt;font-weight:normal;margin-left:78pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Miscellaneous</font><font style="color:#000000;">. </font><font style="font-weight:normal;color:#000000;">This Agreement sets forth the entire agreement between Employee and the Company, and replaces all prior and contemporaneous communications, agreements and understandings, written or oral, with respect to the terms and conditions of Employee&#8217;s employment, other than the </font><font style="color:#000000;">Confidential Information, Non-Disclosure, Non-Solicitation, and Rights to Intellectual Property Agreement </font><font style="font-weight:normal;color:#000000;">dated January 4, 2022, a copy of which is attached as </font><font style="color:#000000;">Exhibit A</font><font style="font-weight:normal;color:#000000;"> and incorporated herein by reference. This Agreement may not be modified or amended, and no breach shall be deemed to be waived, unless agreed to in writing by Employee and an expressly authorized representative of the Board. </font></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-size:11pt;font-weight:normal;margin-left:78pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notice</font><font style="color:#000000;">.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;Any notice required to, or permitted to, be given under this agreement shall be sufficient if in writing (a) delivered personally, (b) sent by first class certified mail, return receipt requested, postage and fees pre-paid, or (c) sent by prepaid overnight delivery service, to the Parties at the following addresses (or at such other addresses as shall be specified by the Parties in a like notice);</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:9.03%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">If to Company:</font><font style="text-decoration:none;margin-left:36pt;">EyePoint Pharmaceuticals, Inc.</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:9.03%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:none;"></font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">480 Pleasant Street</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:9.03%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:none;"></font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Suite A-210</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:9.03%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:none;"></font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Watertown, MA 02472</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:9.03%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:none;"></font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Attention: Jennifer Leonard, Chief People Officer &amp; SVP, IT</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.03%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:76.92%;"><font style="text-decoration:none;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.03%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:9.03%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">If to Employee:</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">Michael Pine</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:9.03%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_Hlk89694313"></a><font style="text-decoration:none;"></font><font style="text-decoration:none;margin-left:36pt;"><a name="_Hlk89694313"></a></font><font style="text-decoration:none;">  xxx</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.03%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:none;">All notices shall be deemed to have been given upon receipt if delivered personally, or by recognized overnight courier, or five (5) days after mailing if mailed.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="font-size:11pt;font-weight:normal;margin-left:78pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Governing Law</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;This Agreement shall be governed by, and construed in accordance with, the laws of the Commonwealth of Massachusetts, without regard to its conflicts of law provisions. Any claim arising out of, or relating to this Agreement including, without limitation, any action commenced by the Company for preliminary and permanent injunctive relief or other equitable relief, shall be instituted in any federal or state court in the Commonwealth of Massachusetts.&nbsp;&nbsp;Each party agrees not to assert by way of motion, as a defense or otherwise, in any such claim, that such party is not subject personally to the jurisdiction of such court, that the claim is brought in an inconvenient forum, that the venue of the claim is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.&nbsp;&nbsp;Each party further irrevocably submits to the exclusive jurisdiction of such court in any such claim.&nbsp;&nbsp;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:7.69%;margin-right:0.21%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-right:0.21%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any and all service of process and any other notice in any such claim shall be effective against any party if given personally or by registered mail, return receipt requested, mailed to such party as provided herein.&nbsp;&nbsp;Nothing herein contained shall be deemed to affect the right of any party to serve process in any manner permitted by law.</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;margin-left:1.23%;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.21%;text-indent:7.69%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.</font><font style="font-size:11pt;font-weight:normal;margin-left:78pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Usage</font><font style="font-weight:normal;color:#000000;">. All pronouns and any variations thereof shall be considered to refer to the masculine, feminine or neuter, singular or plural, as the context may require.&nbsp;&nbsp;All terms defined in the Agreement in their singular or plural forms have correlative meanings when used herein in their singular or plural forms, respectively.&nbsp;&nbsp;Unless otherwise expressly provided the words &#8220;include&#8221; &#8220;includes&#8221; and &#8220;including&#8221; do not limit the preceding words or terms and shall be deemed followed by the words &#8220;without limitation.&#8221;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:0.21%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.</font><font style="font-size:11pt;font-weight:normal;margin-left:78pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Headings</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The headings in this Agreement are for reference only, and shall not affect the interpretation of this Agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">16.</font><font style="font-size:11pt;font-weight:normal;margin-left:78pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Counterparts</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;This Agreement may be executed by the parties hereto in separate counterparts, each of which when so executed and delivered shall be an original, but all such counterparts, together shall constitute one, and the same, instrument.&nbsp;&nbsp;Each counterpart may consist of a number of copies hereof each signed by less than all, but together signed by all of the parties hereto.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.21%;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.21%;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-right:0.21%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;margin-left:1.23%;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.21%;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">IN WITNESS WHEREOF</font><font style="Background-color:#FFFFFF;font-weight:normal;">, the parties hereto have executed this Agreement as of the date first written above.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;">EyePoint Pharmaceuticals, Inc.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/Jennifer Leonard&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="text-decoration:underline;">/s/Michael Pine&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jennifer Leonard&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Michael Pine</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief People Officer &amp; SVP, IT</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date: <font style="text-decoration:underline;">01/05/2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date: <font style="text-decoration:underline;">01/05/2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;margin-left:1.23%;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Confidential Information, Non-Disclosure, Non-Solicitation, and</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rights to Intellectual Property Agreement</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;margin-left:1.23%;text-indent:15.38%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>eypt-ex991_9.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eypt-ex991_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.67 -->
<body>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyqfqrkrrkrk000001.jpg" title="" alt="" style="width:231px;height:45px;"></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WATERTOWN, Mass, January 10, 2022 <font style="font-size:11pt;">(GLOBE NEWSWIRE) </font>&#8211; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the appointment of Michael C. Pine as Chief Corporate Development and Strategy Officer. Mr. Pine brings over 20 years of business and corporate development expertise, leveraging experience from various roles at small and large pharmaceutical companies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are delighted to welcome Michael to our executive leadership team, bringing his impressive track record of successfully generating corporate growth and driving strategy for global pharmaceutical companies,&#8221; said Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals. &#8220;Michael&#8217;s insight and strategic experience will make him an indispensable member of the team as we progress our vision of advancing our pipeline and bringing sustained release delivery technology to patients both in the United States and around the world.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Pine has over 20 years of experience in the pharmaceutical industry, serving in various business development and strategy roles. Most recently, Mr. Pine was a Senior Vice President of Business Development and Strategy at Medexus Pharmaceuticals, where he identified, evaluated and executed several transactions critical to the growth of the organization<font style="font-size:8pt;font-family:Arial;color:#000000;">.</font> Mr. Pine held roles of increasing responsibility at Lupin Pharmaceuticals, Aralez Pharmaceuticals, and Novartis Pharmaceuticals, where he spent over eight years building a diverse skill set in business development, commercial, operational and strategy roles. Earlier in his career, Mr. Pine was in business development roles at Kos Pharmaceuticals, Organon Biosciences, and Pfizer, as well as an Investment Banking Analyst at JP Morgan Chase. Mr. Pine holds a B.S. in Consumer Economics from Cornell University and an M.B.A from Columbia Business School. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;This is a particularly exciting time to be joining EyePoint, as the Company has shifted its focus into growing and developing its promising pipeline,&#8221; said Mr. Pine. &#8220;I look forward to working alongside this talented team as we continue to expand our pipeline and build EyePoint&#8217;s global retinal footprint to improve the lives of patients suffering with ophthalmic diseases.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inducement<font style="color:#000000;"> Grants under Nasdaq Listing Rule 5635(c)(4) </font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the hiring of Mr. Pine, the Compensation Committee of Eyepoint Pharmaceutical&#8217;s Board of Directors granted stock options to purchase an aggregate of 100,000 shares of common stock as an inducement award material to Mr. Pine entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to the closing price of EyePoint's common stock on January 10, 2022, and will vest as follows: 25% on the first anniversary and monthly through the fourth anniversary of the date of grant, subject to the terms of grant.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About EyePoint Pharmaceuticals</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert&#174; technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ&#174;, for the </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:10.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gyqfqrkrrkrk000001.jpg" title="" alt="" style="width:231px;height:45px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU&#174;, for the treatment of postoperative inflammation following ocular surgery. DEXYCU is now sold in the U.S. by </font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImprimisRx</font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, a division of Harrow Health.&nbsp;&nbsp;EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62761624"></a>EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the use of proceeds for the offering and other statements identified by words such as &#8220;will,&#8221; &#8220;potential,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;believe,&#8221; &#8220;intends,&#8221; &#8220;continue,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;may,&#8221; other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint&#8217;s actual results to be materially different than those expressed in or implied by EyePoint&#8217;s forward-looking statements. For EyePoint, this includes uncertainties regarding the timing and clinical development of our product candidates, including EYP-1901; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the continued impact of the COVID-19 pandemic on EyePoint's business, the medical community and the global economy and the impact of general business and economic conditions; the success of current and future license agreements; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; manufacturing risks; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For EyePoint Pharmaceuticals:</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investors:</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christina Tartaglia</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stern IR</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct: 212-698-8700</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">christina.tartaglia@sternir.com</font><font style="color:#000000;"> </font></p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Media Contact:</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amy Phillips</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Green Room Communications</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct: 412-327-9499</p>
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">aphillips@greenroompr.com</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:10.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &nbsp;&nbsp; </p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gyqfqrkrrkrk000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gyqfqrkrrkrk000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ 3$# 2(  A$! Q$!_\0
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M1_BIR/TKU'PA\:8KN6.R\21QV[M\JWD0.PG_ &U_A^HX]@*XZ"2TU!,-"BR
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M*K7N>_7+L]K*MM.JS%3L; ;!^G>N+77?%D5Q80M8O,DZ6SRR_96'E[B#(#]
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M/_BZV/#/Q,TGQ3K"Z9:66H0S-&T@:>-0N!UZ,?6NTHJ'*%M%^)-UV.1^)_\
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M7:>,_P#D1]=_Z\)__0#7%_ O_D3[_P#Z_P!O_1:4E_"8E\)ZA1116)(4444
M>,:W:-8ZU>6Y&-LI*_[IY'Z$50Z5Z!X\T1IHUU6W3+1KMG '.WLWX=__ *U>
M?U\KBZ+I57%[=#[/!5U7HJ2WZ^I@ZKI7E;KFV7]WUDC'\/N/:LBNUZ5@ZII7
ME;KFV7]WU>,#[ON/;^5>SEN9<UJ-9Z]'^C.HR*='&\TJ11HSR.P5549))Z 5
M>TW0M5UB41Z?83SDG&57Y1]6/ _$UZ_X)^'<>@2+J.I,D^H ?(J\I#]/5O?M
MV]:]N4E$X\5C:6'C=N[['EOQ$\"/X8L-*U$,6^T1B*Z!.0DP&>/8C(_X"?6O
M<O!NF-H_@[2;"0;9([=3(/1F^9A^9-,\2:*OB&72[*5<VT%VMW/GN$!VI^)(
M_ &M^LIU'**3/DJE1U'S2W84445D9G%>,?AQ8^*[R+4HKN73]4B "W,0R&QT
MR,CD=B"#]>,80\!>/8QM3QW,5'0L7)_4FO4J*M5))6*YF>?Z'X0\8V.LVMUJ
M/C"2[M8GW26_S8D&#QR:] HHI2DY;B;N<G\1/#=]XI\+'3M/:$3^>DG[UBHP
M,YY /K6EX1TJXT/PIIVF790SV\6QS&<KG)/!_&MJBCF?+RA?2P5YEK_PWU6'
MQ-+XC\'ZHEC>S$O+#+PI8_>P<$$$\[2,9[^GIM%$9..P)V/+A%\7QQ]HTQO?
M$?\ A6UX8B^(*ZRK>(Y[%M/\MMRPA=V[MT%=O15.I=6L@N8_BK1&\1^&;W2%
MG$#7*A1(5W!<,#T_"H/!OAQO"OAJWTE[D7+1,[&0)M!W,3TR?6M^BHYG;E"^
ME@HHHI".8\:>"+#QGIZ0W#F"ZAR8+E%R4SU!'=3Z5QMKHWQ5\/1"SL=0LM1M
M8QB/S6!(';EP#^&2!7K-%7&HTK#4F>27GA;XE>+$^R:WJUI8:>Q_>1PD?,/H
MOWOH6Q7H/A?PQI_A/1TTZP4D9WRRO]Z5_4_X5M442FVK= ;;.'\<> )/%^JZ
M;>)J"VHLP0RM%NW?,#QR/2NOU&T_M#2[NRW[/M$+Q;\9V[E(SC\:LT4G)M)=
M@NSDO ?@K_A"=/NK4W_VPW$HDW>5Y>W QC&376T44FW)W8F[GG'B_P"$EGXG
MUW^U+>_^P/*!]H18-XD/]X<C!QUZYZ^N?1E4*BJ.@&*6BFY-I)]!MME#6]..
MKZ%?Z:)/*-U;O")",[=RD9QWZUB> ?"#^#-%GL)+Q;II;@S;UCV 951CJ?[M
M=512YG:P7TL%%%%(04444 (0&4JP!!&"#WK@/$/@B1)'NM)7?&>6M\\K_N^H
M]OYUZ!16%?#PKQY9G1AL54P\N:!X7)&\4C1R(R.IPRL,$?A3:]MN].LK\8N[
M6&;'0N@)'T/:LQO!^@LVXV 'L)' _G7DSRFHG[LD>W#.J;7OQ=_+^D<IHGCF
M>RC6WU",W$*C"R+]]1_(_I7;6&J-J:AX+*XBA/\ RTN%" _09R?Y4MIH>EV+
M!K>Q@1QT;;EA^)YK0KTL-1K4U:I._P#7<\K%5\/4E>E"W]=@HHHKK.$****
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645F2%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>gxexev5kvbsp000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gxexev5kvbsp000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "^ 3P# 2(  A$! Q$!_\0
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MBB@ HHHH **** "BBB@ HHHH **** "BBH+W4+>P0/,Z_,RA5W<L20 !^)H
MK>)_%7A[P9HL_B+Q3K%O8V-LNZ>YN90B("<#D^I( '4D@#)-?"?[;'_!2_\
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MY/PY'-*L?W^(5[O>-._NQ7;F7O/O=7V"BBBO6/VHTO"WBW7/!VH_VEHEUL+
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MX[E2OY5VX&ISWHSU/POQ)R&.,RMX]Q_>T;*7>4&[*_=Q=K>4F?TJ_P#!//\
M;&\.?MS_ +*7A?X_:.;>'4+ZW-KXETNW<?\ $NU2'Y+B';N9E0M^\CW'<8I(
MF/+5[=7XJ_\ !KK^T;?:-\7/'_[*FK7[-8:UHR^)M'AENL)!=V[QVUQY<9^\
M\T4T!8@YVV8X(''[5 Y&17P6:83ZECITEMNO1Z_AL?RWBJ/L*\HK;H%%%%>>
M<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>FM7"Z<;*\9V:%[><)'YR6^9-@P2J[AOP?S0_P"&[/\ @Y._Z%'XN?\ B/\
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M+\2#[#PO!_\ )5>I?\.*/^"4_P#T:=;_ /A6ZQ_\F4?\.*/^"4__ $:=;_\
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M[NO^4\$O_9W#?^I11PW_ !*_^ >6_;]#^D:/[@K^=W_@X7_Y2@^+/^P'H_\
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M&B1Z[\'OC=X5\26[1J\G]CZ]!.\.X9"R(K;HFZY5PK @@@$$5Y#^WW_P2?\
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MQ5V[*'7:161\/?"%C\/? 6B^ =+EFDM=#TFWT^UDN6#2/'#&L:LQ  +%5!.
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MX)S_  KL-6CM=4N]<\,1^([S4)[<-+-+JC-J!#LP)=D%PL>XGYA&#QTKD_\
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MBQX4_:,\,ZU\3/AO\1X?$GCZWL=0!U1].UN28ZU;^7G,\ZK/!"Q)W;;=N@!
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K ]M6CHDN675ZI6:]-GTM8/9REA^>:VV?Z'VU1117F'&%%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>eypt-20220110.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-01-10T19:54:09.5204597+00:00 -->
<!-- Version            : 5.0.1.725 -->
<!-- Package ID         : 71f793e6bdfa47c59d8acbe55a0d482d -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:eypt="http://eyepointpharma.com/20220110" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://eyepointpharma.com/20220110" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://eyepointpharma.com/20220110/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eypt-20220110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eypt-20220110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>eypt-20220110_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-01-10T19:54:09.5204597+00:00 -->
<!-- Version            : 5.0.1.725 -->
<!-- Package ID         : 71f793e6bdfa47c59d8acbe55a0d482d -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>eypt-20220110_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-01-10T19:54:09.5204597+00:00 -->
<!-- Version            : 5.0.1.725 -->
<!-- Package ID         : 71f793e6bdfa47c59d8acbe55a0d482d -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://eyepointpharma.com/20220110/role/TemplateLink" xlink:href="eypt-20220110.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eypt-20220110.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm140313145431000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 10,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EyePoint Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EYPT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2774444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">480 Pleasant Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">926-5000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>eypt-8k_20220110_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eypt-20220110.xsd" xlink:type="simple"/>
    <context id="C_0001314102_20220110_20220110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
        </entity>
        <period>
            <startDate>2022-01-10</startDate>
            <endDate>2022-01-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0001314102_20220110_20220110" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0001314102_20220110_20220110" id="F_000004">0001314102</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0001314102_20220110_20220110" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0001314102_20220110_20220110" id="F_000002">2022-01-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0001314102_20220110_20220110" id="F_000003">EyePoint Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001314102_20220110_20220110" id="F_000015">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0001314102_20220110_20220110" id="F_000007">000-51122</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001314102_20220110_20220110" id="F_000008">26-2774444</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001314102_20220110_20220110" id="F_000009">480 Pleasant Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0001314102_20220110_20220110" id="F_000010">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001314102_20220110_20220110" id="F_000011">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001314102_20220110_20220110" id="F_000012">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001314102_20220110_20220110" id="F_000013">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001314102_20220110_20220110" id="F_000014">926-5000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0001314102_20220110_20220110" id="F_000018">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0001314102_20220110_20220110" id="F_000019">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0001314102_20220110_20220110" id="F_000020">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0001314102_20220110_20220110" id="F_000021">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0001314102_20220110_20220110" id="F_000016">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001314102_20220110_20220110" id="F_000005">EYPT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001314102_20220110_20220110" id="F_000017">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001314102_20220110_20220110" id="F_000006">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ W8,J5)>*NQS     $P(   L
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -V#*E0KB*9L/00  $T0   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #=@RI4GZ ;\+$"  #B#   #0              @ & #   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( -V#*E27BKL<P    !,"   +
M  "  5P/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( -V#*E0<.&7J/P$  #P"
M   /              "  440  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #=@RI4)!Z;HJT   #X 0  &@              @ &Q$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #=@RI499!YDAD!  #/ P
M$P              @ &6$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  #@$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>122</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="eypt-8k_20220110.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="eypt-8k_20220110.htm">eypt-8k_20220110.htm</File>
    <File>eypt-20220110.xsd</File>
    <File>eypt-20220110_lab.xml</File>
    <File>eypt-20220110_pre.xml</File>
    <File>eypt-ex101_8.htm</File>
    <File>eypt-ex991_9.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "eypt-8k_20220110.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "eypt-8k_20220110.htm"
     ]
    },
    "labelLink": {
     "local": [
      "eypt-20220110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eypt-20220110_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "eypt-20220110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 122,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "eypt",
   "nsuri": "http://eyepointpharma.com/20220110",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "eypt-8k_20220110.htm",
      "contextRef": "C_0001314102_20220110_20220110",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "eypt-8k_20220110.htm",
      "contextRef": "C_0001314102_20220110_20220110",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20220110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001564590-22-000853-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-000853-xbrl.zip
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MQ+-"HI))X-]7\@>Q009_B$6\Q!CIG*MSSY5D8_+QTV**P3-BW*?DK.$T6PV
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M2BF2GO2)&W$D_V]/?,J/_I?-^?]02P,$%     @ W8,J5'N8T)<#!0  N"L
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M'4.6;I3,9>"H[(&&W3"I-WT5RE;5!]7?-LLV1-/'8Q*@.\J[B66^A3*.J?)
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M67.([M$WKC*NU<W_IL,$S&?;:8N!-LYQOK<\:3S.KK')XP71K&XCJCS@L4M
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M.#>EO&W:8L4^;H I) D]K)1H97OE@ 65%)/DVI"N_HKPD\2+Y5#9'VHPB;[
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M\P7!P(W*S,8TWL>?E$4TELU)U(]S)-D":LEF&-(&^U00V&W'!=?ZIMUP/[#
M:<@7J&*-U,,;O6HYLF5LQ88A!K54+HIR/GI_VHKRUQL^1RHJOA4)9ZOLW>U9
MH$U? ]LC6;*XY5$^W[0U$2^@G7E\N=_^DM[XX<F"EHK+A@\.IP2.K>B*FXU?
M=A8\7(L=?0WYA[EG /F  \Q222-T#V18?7UA1?&04L%&*M](Y5H@5B^6(E45
MQJC[!5@=NA?[3!D$!@A,_:"/_MI2>FY:C=:)(*XQWQ*\]\7!B^>BH1W[%5]M
MIU_Q=]C0"#98 $'JS)EXB;6E3;UJ(F:LY& ^S-,8"S_S=-(8\I/R.RME2I-O
M:_8.7[.7XE&=B*"6[*D:0DX"Z2&O^';X&P)^VTG!S.>CV_W1?;V=1_<R08?[
M(L]J9R?W8[ET._+9EVJWPVF^5_7HZ7;-.]40!M" ;8D9*)@J21S_ TI=!*TA
MOW+A+.2G&\NU#ZQK5VCH\FTL89%#D_^8P^3Q.Q<NE-5+W('+JJ4__/5!]SW2
MF;_.':JNH%HX57,!OZF"/#5E;2L<9(LX*!]?;#_(1?GHOGQ]3+8BT%+3^_5)
MW8KP2ULOYH9M2+A>MF,;-V<"-/ :;[@?"_ 7[@$7=V]W#LMH'03:<&!L2_;L
MMKC'='Y;^]#_AET?MY,R'8ZV71 [H2H[Z)(.]>3W(N6=,G@I%Y[RE,".6?I6
MI0^+AW.)J=I1C#I6JFDC5#[Q ;MILK=DB!2+.CG,D/)0:AZ606=#J;+2L"QE
MH14:B,>[ H;LJ_1UW0%-B2'G6R+SDLSS1))$<=(R$+KA#:22U]IW9^.X#7\J
M0YG !ENA4R\WW"E,HFUY16SZKFH=M][TG,RPB$NZ@ V[A_@)&1+.:,9G;\:&
MO1G'1]OISOB"YJQ.9MFH0^.#Y@Y6R?G:_3^729Y U7 E(N$;)J:KS&JX!&%(
M 4=GHT1F8A5%R$*!L0-/4+E"=%4R"N(Q4RF2OOQ'%LO$ESJ]GW*]%?<PTMCY
M)@N\3*VF/2[::6G\))0VW3@,!$?*V,NFJ M@,:P2 Q0&2GBBU NLEDA4?RR)
ME@]J8%$(8H$H4FE,):JA?>F;;N$'RZ<7WC6'L^JK[UN3:)B@,^A0DIKYSR4>
M3O)2S^E&2<>_5SJ55\]T*H_UUM60_:O/Y_.EV.)2/-[.2_$WF7@B"'@HHFRS
M:/^J)8AT4U3C-^?MB(5%"CD4Z:T0R^R_6,P"CO</"GGEN%=U%T%H3C&=E<9%
MA#99J&^V9% THYS0-#V&# 5I)+7O'V,$,6;'-E$N8FG#Q+3F:R;R)CQ"411R
M4"5*;#/A[VPHP8<".S!@'Z-P_[T")H ]K7[^8C$YJBGZK)SMT&NL)1H@4202
M0%XK<_W>6A+'A?6)$/,?/,P0W7 V8"=')R<JHWA&24]:"8#)2E.XNA5[9INA
M7]U-Y!"4A\4%/9=8&#A^&9K,9FA8%;1DE&RB"WG6?!08K-#ZQS3R575*W%>*
M8%I-:AB99)%<O_#QZWELF,LY/JLY0&F_T>^@<=Q=Z-Z 3I0V-Y6.Q0R8!!TK
M&:A1,0@&OTB+475$;:;6XC NO$[.5KQ.GBT>!^%^LIW"_6.42J_1&U:3ZHXG
MS(92789T;I#:UD)*D&U1Z-/X 9R/,>SDT(9D\+K"GF3(DROQ,Z0++P[.+M^#
MTQ; *[")&?EIT1LY(+)IBM;"V1I)$.E(D@WGST/')!UDL(% GL<BS>(0_O&$
MG*7478&T50,P*^ >&*L#.4) &)R]_1F7OJ+L]HKWPR_P<Q9!-T*<(].G>U.Q
M=V"NBFNN_*(ZC:U@V.2^C^<=2;Q1PJ2:34NA3O+?<:MH<%$P5Z-.S+MA?I"T
MX:O0:[!WX>@?>31R#GOSOSXX.EWFAUFJG3XR5P>8^;"^6AUYT^:DTA?M89\J
M4H&K>W$=2?C>]81#!SR1P0KR #21#Z&WP/;L9L9[F^+ZO=!NTM>9YM;?W?GI
M[-41NT9V.B3C_Y*";$J?E^'QE^%+)E/!+O=/CH^>I__QI_]WT)GCE'B4?[MD
M1R=G+T^>E^'QE^$2C5'Z@/U#A*'$:.RO G2>&+22=Q,I1NQ:1+- L$]462!F
M?^'3V07[\E_7<(/<=! GV:;U>7'P^F3%!7)SCJVJGSRK1A75R%BW:^E&*YR3
MWZ0WX2)@U[* /7W_<HJSD$]A;/_]2_#UU>L7K\].CT]QVOCF1=@#3;=?-<;N
M[NXZDU%.1W1[;*+MVEIM[B85K)/H@VUPA5$1UB'Z<;7%CY >8W:#5=]LQJLZ
M7_!8- [)!5;8V!COE%B/")X9H3ML]WR/^?P>K&2"*Z%]3_4B1O1?X7=)>F1[
MK9Y]9FOZS$ZWTV?V=[778 O]RF\=O6*E#,-&!!RZP*@A<N0,3!@A2>,,H^-8
M"@KZZE..HZHHC+Z>@-_:C*W3*+P5/$@) ?<;3Q+N3;($UBDI$AIB,48N<_0\
MITE.:)28+(@\<IX<,/3?>0&74\9U)2Q\030:J*)2=NGDTHB6EC&Y9]Q4L)I.
MT>5>2YFB6H/0A,2J7_&]"NH+S/%4#?R1A:J"&#X#ZFZ>FH5^QI0"^>HW@V)^
MI:EWIN836Q&PZ IT0.R:&CRA*\ ].*'EG%'"'U"ZILX:Q7 !(CB2!.PE'-PM
MI\C'--)S@+5;?#$282(JF2>Z;^3XH]D?6+SZJA'%TL$,0T8A*8U_T49\Y+@-
M&MR@(,]22POO&E(]EU2U3.&1$$0S^5EA';*I]1WX/"M*"I@7R*G">BK4"#U:
MS<(AMB[=WRE'R4&A%YR2(KJB<1BT/DKD%QU?-.$C^!TNO(QC,8\POPZ_-9Q*
M%>)2)/VP'Q/<+8OGI3[MI0:71E5.EJJ*2G#K3RCA!8D*NP>;+55<%[7=.Q_R
M9:@..IY7[3'7M><\BIE12.Q>'W0=6*@M6W'>BS*#FJ5$%W"G$S32^H=U=HR2
M,<:"%7&+T(#2)_(B*EH )'FQ1!U<+&VDCQ$6DQV;N"/&I54=T09=28&=%%:+
M=)V\!CTVA,W")(E\?O14P,J$(FY"+#TU1-'K9T11_XBB]D+G69GN4)D^VTYE
M^I\)G 57)9I12G\<A3 +Q75 4ZG -JE6*7)9BAHT2&*=HD\(#Z,43'GB9=C'
M :B!F'>@JMF% A1$L"91W<VPF! JHD%&H!]54TMAB>X4+$3'M4LB'GNIL$"F
M:+I6*&T-65?GJC>#*A=\E>QDF%"E9L_STN-81A'-YJ3 KBQ]V<#*A GN2WW]
MIX*CY.JG!3C);S'L^BW8'@E#!-/)T872[PG/=')\4?DT,1_C^I1^!;TSO_,C
M4OG(*M IUG"]4HZ/:@DUQAQ.5;T:5;B\,!I*G:M;' >ZU0Y<2H^EPSUUZ76^
MG=+K%\$)$-B-%P!ICM7[U!$N\Q?'JF9WCDIC41AHOT"!B+<T1*(X@&-4U&RN
MD!QM!_KCJ>_L%]NYL]\AH0WL'[ L.MK=-03ET%3+*P3W3$.5\")34,A$P&?:
M$Y-W:)!G=2K@*-V 252\#@]%X3C.KPLLS@A"6H9X>0_A3B##4IO\UMO3:"S(
MIE3?)+<;.8JPQ.T@QQECC<T!>9'BK$X;QLNOI2&3^I$HNXV%F:D-[T4S,VKX
M28%&X:AH4PWO8\(#0U]4MXO^Y4]9)7O+D[AF$MQ*OH'-FP1/T@WR?V]^N6*?
MKWZ[_/#Q_=5G]NEG=O/+AR_L^O+O5PS^_?#QYNKCS8=/'R]__?5?[->KGV_8
MVU\O/_[O_]>M9'_4"/(P9H=/L((T@IB>/11]>R@ZSWGJ3]C2D\ME8FM5J[TT
MZ 0\4M>E?J8_""#YR'[_<//QZLL7]OLO5Y^O/OW<I*8L?$'#R3645!4EA SO
M7+.H:N5YM(VX,Q2BW"0'\6$T%UNB9KN66GQ4J=].5:V MMS^9@NU6=KM;HCK
M->>Z>RG8_JVM#+3MV2IO[]^PUMOE,#FLHB+7VCIK?9EUL'E+@<@59L&&OVUD
M=-OP]_*$MV]PO[<9>)=[_%OYFY41G4_E,M3.HS8SM";ZNWOFBF_^Q=^AZ'@/
MRNL*%^K1\>'1^2$F<6^##%AV$73UON]RDEPGM0L=U2&^OS8H]]',V*?JP3I^
M]F!]AQZL!W>NVXE_K)-X]7]^^?#VPPU2A&QZ2*M[:;ZUR5R3:N;[F8C6G#E/
M\ HXZ>\*^/%P&/GW>!,<3M)I /_Y_U!+ P04    " #=@RI4E?5O%L0.  #?
M0   $    &5Y<'0M97@Y.3%?.2YH=&WM7&USVS82_MZ9^P^H.^VE,WJQ'.?%
MEILYV582]_Q62TDNGSH0"8F(08(!0,G*K[]G 9*27^1KTZ3QQ>ET:@<$@=W%
M[K//+MCL?+]_LC=\>]IG+X='A^STU>[AP1Y;:[;;;Q[NM=O[P_WP8+.UWF%#
MPS,KG=095^UV_WB-K27.Y=OM]FPV:\T>MK29M(=G[<2E:K.MM+:B%;MX[=D_
MOMNA,?]3\)A^.NF4P"]BGKNFN-C:ZOR^U<(D/&I7SW;:U>SOFTUV_(+MZ6PJ
MC!.&31^UUEL;K<=/6+-)$T8ZGN/G=SLYLVZNQ"]K3ERX)E=RDFV_*ZR3XWDW
MY68BL^9(.Z?3[?7<52-.Y_Z/_AV9Q2)SV^L_=L<Z<TTK/XCMSGKK$9[[@3%/
MI9IO]XSD*HS,A)PD;CO3)JV&O!#5B%_6D?'&&,!H)L*L*<<BV(N5$]>>[<AT
MPJR)?EF;S-^/WYMS@W_/U^F?3NM=/EECWCB_K*TQKAS]*-6=R=@EVQL/._E%
M-PGR;#["[UBRG3^[V2Z&IGV<54J51UK%W4@K;;9_\$*N+QNM<\UH0YD*RX[%
MC)WIE&=_S5;]BT2.I&-;6ZW.:B4CB"W,QVEYF]3+%KBN]-JSG[*1S;N?1ZX[
M8?VY.-4R<^PTX1B*1.%DQ)5EO3RG<<N.9)1PH=A>BYW*3#!NV5XBQ1AA;')M
MN!-L7TR%TGD*Y1C/8C9P-#R9LY/Q6$;"W*]C_9QR?2P&_E7W^H38^*8W[)\-
M3]X<-]@1M[;!?N59P<V<==8;;&-]8X/MT)N5\LNR>A,]>'%XLMMGQ_TW@S<'
M9_V?V4Z;YCS[Z8>G&YU.EZWRZ 8[R*(6>W#<&^SW?MMF_;>GPY\;C+/\TCP6
MZ33GV9Q^IM(Y$3.G61P\7&83[^#T3)@(J4-^H#&7",-SOX*EZ8E0.9-I;O14
MT$.FY!1&U6.6<R<%A=5,NH198:0N+!-SP6)IM8F%@:!.QWR.C3)=9!$)@!5X
MB$<?8UCG$T1EBQV9\NV1@1:0#VD91\#F@ALO[:BP>&QMJ72U<KRTLKC(D<NE
M%0VF,&SXA SB1Z%H)-C8Z)21&Y"B1BO8@>-TX0S*+ZO@N.+F0Y#"MJ[$PB>/
MR'L7?Q0G&^O=-_ 90T>I:.7@Y3.A8'A1.Q>&=&%PF"+"N<"5%8@</#21.7."
MIXW@.'3@B;3>X>$L-!&B1.?,"/A,3(YDBRC"HW&AU)Q-1 8_<?3:PJ<F1L\0
M$>01L9%3>F@KAX5.;*+T"(ZQRD\:7BV$O^4R9L<\B^;LL##GPC3*P.C76I3^
M3W*M HL6*\U4FL*#RY,N= 1UAKV\G*5\,EIV]YF$7Z?\7, D*:;A#41V+C++
M1TJP5*2CL#4%-1F10G>& #!Z0M;S%I]*"WI.LW@\A2YD#1K/98[SHG#']K7M
M+9R28S2&P7%"-IPJ8G&.#:(D@^_!B#C,&GS@MPD$\S*\RB0=_\!!EQ#HW !W
M NK,M%%QJ[3MMU#\Q*%8XV_";P#?):<JC^J*\T,GV,#,&Y1'?,1@7H6T-73'
M5]) '54>BY$$M'44J7BNL%0MTPPR<380F43TO4; L%/XIXS+!+1;K;\RS0#E
MCT0L+B#,M50\0\*$VM",UI-C*>(&$U.N"D[.2.L$U,$?K$\KBGF;\H@*5\LB
M(X,1X-9DFA(^RKA"!0M4^,!I[@HV\?3&0O"R<ZP]:Y7D8F$6I/:X3&/83&:1
M0<21[6&<')*AEE'2>>T/"Q"&Z[KWH(SX<'V<E#[6.#]DTULL1ECB@K=X3RP=
M9E1(%7M^ B:!AT !>TY89(4CO[C)'QI+1*;!=.Y1F=H"-SI*GQLEL2L6([2/
MD#X(72\YS(J-%GG_W_H&W4[HN(!WNU+;R'M\:8[3,8X*>WB()+Y   4>!S(5
MF- NS\Y)Z1Z$GL./L<.OIW!I6A"X#RQ<8CD)6#?Y]&YKT"))]W!<!=1G_4AG
M.B7NYLD**%1&NP$9R9#^- D6,W;4VFWUJDFJ2$>2+P)A$"5:JQ;[!I.?A[$,
M/<>@ \PI1J("S!%L0EQ$TG,)!S$(#D:"O4-.IZ$JO7L/(F#8*\D] 2YHS)CP
M12(ACG54D/?B=4*2BN<OT7Z:A1R=2A_L52*^3#LJ3ZO9PP%36I\3?YEQ$RB6
M-MYAN=)@W$ _B 6='" A\RQLP0C@E-"K\#HA%Y \USD 17VM9LU22K)D!!;
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M="TR,#(R,#$Q,%]L86(N>&UL4$L! A0#%     @ W8,J5'N8T)<#!0  N"L
M !4              ( !-0P  &5Y<'0M,C R,C Q,3!?<')E+GAM;%!+ 0(4
M Q0    ( -V#*E0?/U1,UQD  .ZV   4              "  6L1  !E>7!T
M+3AK7S(P,C(P,3$P+FAT;5!+ 0(4 Q0    ( -V#*E1FXG<=23L  +?T 0 0
M              "  70K  !E>7!T+65X,3 Q7S@N:'1M4$L! A0#%     @
MW8,J5)7U;Q;$#@  WT   !               ( !ZV8  &5Y<'0M97@Y.3%?
;.2YH=&U02P4&      8 !@"# 0  W74

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
